Reductions in QEEG Slowing over 1 Year and After Treatment with Cerebrolysin in Patients with Moderate-severe Traumatic Brain Injury

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2008 Feb 15

PMID 18273537

Citations 11

Authors

X Anton Alvarez

Carolina Sampedro

Jesus Figueroa

Ivan Tellado

Andres Gonzalez

Manuel Garcia-Fantini

Ramon Cacabelos

Dafin Muresanu

Herbert Moessler

Affiliations

Soon will be listed here.

Abstract

Changes in quantitative EEG (qEEG) recordings over a 1-year period and the effects of Cerebrolysin (Cere) on qEEG slowing and cognitive performance were investigated in postacute moderate-severe traumatic brain injury (TBI) patients. Time-related changes in qEEG activity frequency bands (increases of alpha and beta, and reductions of theta and delta relative power) and in qEEG slowing (reduction of EEG power ratio) were statistically significant in patients with a disease progress of less than 2 years at baseline, but not in those patients having a longer disease progress time. Slowing of qEEG activity was also found to be significantly reduced in TBI patients after 1 month of treatment with Cere and 3 months later. Therefore, Cere seems to accelerate the time-related reduction of qEEG slowing occurring in untreated patients. The decrease of qEEG slowing induced by Cere correlated with the improvement of attention and working memory. Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials.

Citing Articles

QEEG indices in traumatic brain injury - insights from the CAPTAIN RTMS trial.

Olivia V, Chira D, Chelaru V, Diana C, Livia L, Buruiana A J Med Life. 2024; 17(3):318-325.

PMID: 39044922 PMC: 11262599. DOI: 10.25122/jml-2024-0187.

A Modern Approach to the Treatment of Traumatic Brain Injury.

Syzdykbayev M, Kazymov M, Aubakirov M, Kurmangazina A, Kairkhanov E, Kazangapov R Medicines (Basel). 2024; 11(5).

PMID: 38786549 PMC: 11123131. DOI: 10.3390/medicines11050010.

Neuroprotective and neuroregenerative drugs after severe traumatic brain injury : A narrative review from a clinical perspective.

Grgac I, Herzer G, Voelckel W, Secades J, Trimmel H Wien Klin Wochenschr. 2024; 136(23-24):662-673.

PMID: 38748062 DOI: 10.1007/s00508-024-02367-9.

A retrospective study of Cerebrolysin in patients with moderate to severe traumatic brain injury: Cognitive and functional outcomes.

Soto C, Salinas P, Munoz D, Olivares S, Gonzalez J, Saez V J Med Life. 2023; 16(7):1017-1021.

PMID: 37900065 PMC: 10600656. DOI: 10.25122/jml-2023-0125.

Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study.

Strilciuc S, Radu C, Grad D, Stan A, Vladescu C, Buzoianu A Healthcare (Basel). 2023; 11(10).

PMID: 37239783 PMC: 10218347. DOI: 10.3390/healthcare11101497.

References

Boly M, Faymonville M, Peigneux P, Lambermont B, Damas P, Del Fiore G . Auditory processing in severely brain injured patients: differences between the minimally conscious state and the persistent vegetative state. Arch Neurol. 2004; 61(2):233-8. DOI: 10.1001/archneur.61.2.233. View

Nagata K, Tagawa K, Hiroi S, Shishido F, Uemura K . Electroencephalographic correlates of blood flow and oxygen metabolism provided by positron emission tomography in patients with cerebral infarction. Electroencephalogr Clin Neurophysiol. 1989; 72(1):16-30. DOI: 10.1016/0013-4694(89)90027-8. View

Faden A . Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr Opin Neurol. 2002; 15(6):707-12. DOI: 10.1097/01.wco.0000044767.39452.bf. View

Lombardi V, Windisch M, Garcia M, Cacabelos R . Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp Clin Pharmacol. 1999; 21(5):331-8. DOI: 10.1358/mf.1999.21.5.541910. View

Chiaretti A, Piastra M, Polidori G, Di Rocco C, Caresta E, Antonelli A . Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury. Intensive Care Med. 2003; 29(8):1329-38. DOI: 10.1007/s00134-003-1852-6. View

RUETHER E, Alvarez X, Rainer M, Moessler H . Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002; (62):265-75. DOI: 10.1007/978-3-7091-6139-5_24. View

Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H . Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl. 2002; (62):327-36. View

Winter C, Pringle A, Clough G, Church M . Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain. 2003; 127(Pt 2):315-20. DOI: 10.1093/brain/awh039. View

Kane N, Moss T, Curry S, Butler S . Quantitative electroencephalographic evaluation of non-fatal and fatal traumatic coma. Electroencephalogr Clin Neurophysiol. 1998; 106(3):244-50. DOI: 10.1016/s0013-4694(97)00141-7. View

10.

Savola O, Pyhtinen J, Leino T, Siitonen S, Niemela O, Hillbom M . Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma. 2004; 56(6):1229-34. DOI: 10.1097/01.ta.0000096644.08735.72. View

11.

Coles J, Steiner L, Johnston A, Fryer T, Coleman M, Smieleweski P . Does induced hypertension reduce cerebral ischaemia within the traumatized human brain?. Brain. 2004; 127(Pt 11):2479-90. DOI: 10.1093/brain/awh268. View

12.

Saletu B, Hitzenberger G, Grunberger J, Anderer P, Zyhlarz G, Linzmayer L . Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. Int J Clin Pharmacol Ther. 1995; 33(5):249-62. View

13.

Rapoport M, McCauley S, Levin H, Song J, Feinstein A . The role of injury severity in neurobehavioral outcome 3 months after traumatic brain injury. Neuropsychiatry Neuropsychol Behav Neurol. 2002; 15(2):123-32. View

14.

Akai F, HIRUMA S, Sato T, Iwamoto N, Fujimoto M, Ioku M . Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol. 1992; 7(2):213-21. View

15.

Csuka E, Morganti-Kossmann M, Lenzlinger P, Joller H, Trentz O, Kossmann T . IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol. 1999; 101(2):211-21. DOI: 10.1016/s0165-5728(99)00148-4. View

16.

Alvarez X, Sampedro C, Perez P, Laredo M, Couceiro V, Hernandez A . Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol. 2003; 18(5):271-8. DOI: 10.1097/00004850-200309000-00003. View

17.

Gschanes A, Windisch M . The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neural Transm Suppl. 1998; 53:313-21. DOI: 10.1007/978-3-7091-6467-9_27. View

18.

Teasdale G, Jennett B . Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974; 2(7872):81-4. DOI: 10.1016/s0140-6736(74)91639-0. View

19.

Thatcher R, North D, Curtin R, Walker R, Biver C, Gomez J . An EEG severity index of traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2001; 13(1):77-87. DOI: 10.1176/jnp.13.1.77. View

20.

Alvarez X, Mouzo R, Pichel V, Perez P, Laredo M, Fernandez-Novoa L . Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 2000; 21(9):633-44. View